Exagen Inc (XGN) just unveiled an update.
Exagen Inc. is set to undergo a significant change in its Board of Directors with the resignations of Brian Birk, Wendy Johnson, and Ebetual Pallares effective June 10, 2024. No disagreements prompted the departures, which precede the appointment of Scott D. Kahn, Ph.D., as a new Class I director on the same date. Dr. Kahn brings a wealth of experience in health data privacy and has held leadership positions in several organizations. His arrival coincides with a reduction in the Board’s size from nine to seven members, aligning with the company’s governance adjustments. Dr. Kahn’s qualifications and independence have been rigorously assessed, ensuring he meets Nasdaq Global Market and SEC standards for board membership.
For an in-depth examination of XGN stock, go to TipRanks’ Stock Analysis page.
